Matthew Campobasso - Enfusion General Secretary
| ENFN Stock | USD 11.10 0.01 0.09% |
Executive
Matthew Campobasso is General Secretary of Enfusion
| Age | 45 |
| Address | 125 South Clark Street, Chicago, IL, United States, 60603 |
| Phone | 312 253 9800 |
| Web | https://www.enfusion.com |
Matthew Campobasso Latest Insider Activity
Tracking and analyzing the buying and selling activities of Matthew Campobasso against Enfusion stock is an integral part of due diligence when investing in Enfusion. Matthew Campobasso insider activity provides valuable insight into whether Enfusion is net buyers or sellers over its current business cycle. Note, Enfusion insiders must abide by specific rules, including filing SEC forms every time they buy or sell Enfusion'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Matthew Campobasso over three months ago Disposition of 674 shares by Matthew Campobasso of Enfusion at 8.95 subject to Rule 16b-3 |
Enfusion Management Efficiency
The company has return on total asset (ROA) of 0.0305 % which means that it generated a profit of $0.0305 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0442 %, meaning that it created $0.0442 on every $100 dollars invested by stockholders. Enfusion's management efficiency ratios could be used to measure how well Enfusion manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of March 2025, Return On Tangible Assets is likely to grow to 0.02. Also, Return On Capital Employed is likely to grow to 0.06. At this time, Enfusion's Asset Turnover is very stable compared to the past year.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Suresh Balasubramanian | Meridianlink | N/A | |
| Joe Jacobson | CS Disco LLC | N/A | |
| Susan JD | Braze Inc | 66 | |
| Kevin Smith | CS Disco LLC | 45 | |
| Alice Geene | Paycor HCM | 52 | |
| Nicole McGougan | Blackbaud | N/A | |
| Aleksey Lakchakov | CS Disco LLC | N/A | |
| Joon JD | Clearwater Analytics Holdings | N/A | |
| William Weesner | ON24 Inc | N/A | |
| Michael Jahoda | PROS Holdings | 45 | |
| Mike Chen | Clearwater Analytics Holdings | N/A | |
| Colleen Langevin | PROS Holdings | N/A | |
| Damian JD | PROS Holdings | 50 | |
| Priyanka Singh | Braze Inc | 55 | |
| Kayla JD | Meridianlink | N/A | |
| Catherine LaCour | Blackbaud | N/A | |
| Doug Farber | Freshworks | N/A | |
| Joe Frassica | Paycor HCM | N/A | |
| Brian Wheeler | Braze Inc | N/A | |
| Damian Olthoff | PROS Holdings | 49 | |
| May ONeal | ON24 Inc | N/A | |
Management Performance
| Return On Equity | 0.0442 | ||||
| Return On Asset | 0.0305 |
Enfusion Leadership Team
Elected by the shareholders, the Enfusion's board of directors comprises two types of representatives: Enfusion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enfusion. The board's role is to monitor Enfusion's management team and ensure that shareholders' interests are well served. Enfusion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enfusion's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephen Dorton, Chief Officer | ||
| Michael Berry, Chief Officer | ||
| Lorelei Skillman, Chief Officer | ||
| Vivek Ranka, Head Technology | ||
| Stephen Malherbe, Managing Partner | ||
| Oleg Movchan, Interim Director | ||
| Matthew Campobasso, General Secretary | ||
| Bronwen Bastone, Chief Officer | ||
| Joseph Defeo, Global Production | ||
| Lotte Tonsberg, Head EMEA | ||
| Kabir Kohli, MD Services | ||
| Jeff Young, Head Implementation | ||
| Iris Wang, Chief Officer | ||
| Brian Murphy, Investor | ||
| Matt Campobasso, General Counsel | ||
| Robert Taylor, Head Support | ||
| Ignatius Njoku, Head Relations | ||
| Bradley Herring, Chief Officer | ||
| Neal Pawar, Chief Officer | ||
| Daniel Groman, Chief Officer | ||
| Valeria Gutowski, Chief Officer |
Enfusion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enfusion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0442 | ||||
| Return On Asset | 0.0305 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 1.02 B | ||||
| Shares Outstanding | 94.8 M | ||||
| Shares Owned By Insiders | 4.73 % | ||||
| Shares Owned By Institutions | 96.01 % | ||||
| Number Of Shares Shorted | 948.03 K | ||||
| Price To Earning | 0.11 X |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.82) | Earnings Share 0.03 | Revenue Per Share | Quarterly Revenue Growth 0.139 | Return On Assets |
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.